Details for Patent: 6,630,514

Title:	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
Abstract:	The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan, or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan
Inventor(s):	Youdim; Moussa B. H. (Haifa, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel Aviv, IL), Sterling; Jeffrey (Jerusalem, IL)
Assignee:	Teva Pharmaceutical Industries, Ltd. (IL) Technion Research and Development Foundation, Ltd. (IL)
Filing Date:	Oct 26, 2001
Application Number:	10/016,268
Claims:	1. A method of treating an affective illness in a subject which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat the affective illness in the subject. 2. The method of claim 1, wherein the pharmaceutically acceptable salt of R(+)-N-propargyl-1 aminoindan is selected from the group consisting of: the mesylate salt; the esylate salt; the sulfate salt; and the hydrochloride salt. 3. The method of claim 2, wherein the pharmaceutically acceptable salt is the mesylate salt of R(+)-N-propargyl-1-aminoindan. 4. The method of claim 1, wherein the effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof to be administered is from about 0.5 milligrams per kilogram body weight of the subject to about 2.5 milligrams per kilogram body weight of the subject. 5. The method of claim 1, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered intravenously, orally, rectally, transdermally, or parenterally. 6. The method of claim 5, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered intravenously. 7. The method of claim 5, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered orally. 8. The method of claim 1, wherein the subject is human and the effective amount is from about 0.01 mg to 50.0 mg per day. 9. The method of claim 8, wherein the effective amount is from about 0.1 to 10.0 mg per day. 10. The method of claim 1, wherein the R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is supplemented with a pharmaceutically acceptable carrier, and wherein the pharmaceutically acceptable carrier is a solid and the pharmaceutical composition is a tablet; the pharmaceutically acceptable carrier is a liquid and the pharmaceutically composition is an injectable solution; or the pharmaceutically acceptable carrier is a gel and the pharmaceutical composition is a suppository. 11. The method of claim 10, wherein the amount of the salt in the tablet is an amount from about 0.1 mg to about 100 mg; and the amount of the salt in the injectable solution is an amount from about 0.1 mg/ml to about 100 mg/ml. 12. The method of claim 11, wherein the amount of the salt in the tablet is an amount from about 1 mg to about 10 mg; and the amount of the salt in the injectable solution is an amount from about 1 mg/ml to about 10 mg/ml. 13. A method of treating schizophrenia in a subject which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat the schizophrenia in the subject. 14. The method of claim 13, wherein the pharmaceutically acceptable salt of R(+)-N-propargyl-1 aminoindan is selected from the group consisting of: the mesylate salt; the esylate salt; the sulfate salt; and the hydrochloride salt. 15. The method of claim 14, wherein the pharmaceutically acceptable salt is the mesylate salt of R(+)-N-propargyl-1-aminoindan. 16. The method of claim 13, wherein the effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof to be administered is from about 0.5 milligrams per kilogram body weight of the subject to about 2.5 milligrams per kilogram body weight of the subject. 17. The method of claim 13, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered intravenously, orally, rectally, transdermally, or parenterally. 18. The method of claim 17, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered intravenously. 19. The method of claim 17, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered orally. 20. The method of claim 13, wherein the subject is human and the effective amount is from about 0.01 mg to 50.0 mg per day. 21. The method of claim 20, wherein the effective amount is from about 0.1 to 10.0 mg per day. 22. The method of claim 13, wherein the R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is supplemented with a pharmaceutically acceptable carrier, and wherein the pharmaceutically acceptable carrier is a solid and the pharmaceutical composition is a tablet; the pharmaceutically acceptable carrier is a liquid and the pharmaceutical composition is an injectable solution; or the pharmaceutically acceptable carrier is a gel and the pharmaceutical composition is a suppository. 23. The method of claim 22, wherein the amount of the salt in the tablet is an amount from about 0.1 mg to about 100 mg; and the amount of the salt in the injectable solution is an amount from about 0.1 mg/ml to about 100 mg/ml. 24. The method of claim 23, wherein the amount of the salt in the tablet is an amount from about 1 mg to about 10 mg; and the amount of the salt in the injectable solution is an amount from about 1 mg/ml to about 10 mg/ml. 25. A method of treating a subject suffering from the symptoms of withdrawal from an addictive substance which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat the symptoms of withdrawal in the subject. 26. The method of claim 25, wherein the pharmaceutically acceptable salt of R(+)-N-propargyl-1 aminoindan is selected from the group consisting of: the mesylate salt; the esylate salt; the sulfate salt; and the hydrochloride salt. 27. The method of claim 26, wherein the pharmaceutically acceptable salt is the mesylate salt of R(+)-N-propargyl-1-aminoindan. 28. The method of claim 25, wherein the effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof to be administered is from about 0.5 milligrams per kilogram body weight of the subject to about 2.5 milligrams per kilogram body weight of the subject. 29. The method of claim 25, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered intravenously, orally, rectally, transdermally, or parenterally. 30. The method of claim 29, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered intravenously. 31. The method of claim 29, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered orally. 32. The method of claim 25, wherein the subject is human and the effective amount is from about 0.01 mg to 50.0 mg per day. 33. The method of claim 32, wherein the effective amount is from about 0.1 to 10.0 mg per day. 34. The method of claim 25, wherein the R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is supplemented with a pharmaceutically acceptable carrier, and wherein the pharmaceutically acceptable carrier is a solid and the pharmaceutical composition is a tablet; the pharmaceutically acceptable carrier is a liquid and the pharmaceutically composition is an injectable solution; or the pharmaceutically acceptable carrier is a gel and the pharmaceutical composition is a suppository. 35. The method of claim 34, wherein the amount of the salt in the tablet is an amount from about 0.1 mg to about 100 mg; and the amount of the salt in the injectable solution is an amount from about 0.1 mg/ml to about 100 mg/ml. 36. The method of claim 35, wherein the amount of the salt in the tablet is an amount from about 1 mg to about 10 mg; and the amount of the salt in the injectable solution is an amount from about 1 mg/ml to about 10 mg/ml.